Clinical Framework for Managing Hypogonadism and Low Testosterone in Men

Low testosterone is one of the most over-diagnosed and under-diagnosed conditions in men’s health. Over-diagnosed because the symptoms (tiredness, low mood, reduced libido, loss of motivation) overlap with many other conditions: depression, chronic stress, undiagnosed thyroid disease, obstructive sleep apnoea, even iron deficiency. Under-diagnosed because most men never get tested properly, and many who do are tested at the wrong time of day with the wrong markers.

This article is the clinical reference document our team uses when we work through a suspected low testosterone case at 134 Harley Street. It is structured for clinicians, written in clinical language, and aligned to the British Society for Sexual Medicine and European Association of Urology guidelines. If you are investigating your own symptoms and want a friendlier overview of what low testosterone feels like and what testing involves, look out for our patient-facing companion piece. If you want the full evidence base and the protocol our doctors actually follow, read on.

Executive Summary

This paper establishes an evidence-based clinical framework for the identification, diagnosis, and management of male hypogonadism. It addresses the physiological complexities of androgen production, the systemic nature of symptom presentation, modifiable lifestyle drivers, and regulatory safeguards. Designed for implementation within premier clinical settings, this framework prioritises diagnostic precision and patient safety through rigorous adherence to established endocrine guidelines.

Core Medical Premises and Physiological Accuracy

Free Testosterone

A persistent flaw in public health literature is focusing entirely on Total Testosterone. To ensure diagnostic accuracy, clinical evaluations must distinguish between total hormone levels and bioavailable hormone levels. The critical factor is Sex Hormone-Binding Globulin (SHBG), a protein that binds tightly to testosterone. Because of this high-affinity binding, a patient can present with a seemingly normal total score but suffer from severe clinical symptoms if elevated SHBG levels leave insufficient bioavailable, free hormone for tissue utilisation. [1]

Free testosterone measurement is most informative when total testosterone falls in a borderline range or when clinical symptoms persist despite apparently normal total levels. Calculated free testosterone, derived from total testosterone, SHBG, and albumin, is generally preferred over direct immunoassay methods, which carry poor accuracy at the low concentrations encountered clinically. [2]

The Diurnal Rhythm

Endocrine evaluation requires strict scheduling due to natural hormonal fluctuations. Sampling must occur in the morning, ideally between 07:00 and 11:00, and in a fasting state. Testosterone levels naturally peak in the early morning and decline significantly by the late afternoon, meaning a late-day or post-prandial sample can easily produce a false positive result for hypogonadism. [3,4]

The Oestradiol Balance

Comprehensive androgen profiling must account for downstream metabolic pathways, specifically those involving Oestradiol and Dihydrotestosterone (DHT). Testosterone aromatises into oestrogen via the aromatase enzyme, a conversion that is substantially amplified in the presence of visceral adipose tissue. Consequently, the ratio between androgens and oestrogens is just as clinically significant as the absolute testosterone value. DHT, produced via 5-alpha reductase activity, is relevant to prostate health and virilisation and should be considered where clinical presentation warrants. [5]

Nuanced Symptom Profiling and Differential Diagnosis

Overlapping Presentation

The clinical presentation of low testosterone is rarely single-faceted; it manifests as a systemic cluster of metabolic, physical, and psychological changes. Many symptoms lack specificity, meaning that fatigue, low mood, and loss of motivation closely mimic clinical depression, chronic stress, or hypothyroidism. Confirmation of a clinical suspicion by hormonal testing is mandatory rather than optional. [6]

Physical Indicators

To differentiate hypogonadism from general ageing or burnout, clinicians must identify specific physical indicators. Differentiating physical signs include loss of spontaneous and morning erections, reduced exercise tolerance, and gynaecomastia. These are more specific to androgen deficiency than generalised fatigue or mood disturbance and carry greater diagnostic weight.

The Threshold Nuance

Objective laboratory values must be interpreted alongside subjective clinical presentations. There is no universal threshold at which symptoms reliably appear. Symptom onset depends on individual receptor sensitivity, carrier protein concentrations, and baseline hormonal trajectory. A combined biochemical and clinical approach is required, and neither criterion should be applied in isolation. [6]

High-Risk Demographics and Modifiable Factors

The Adipose Tissue Loop

Accelerated testosterone decline is frequently driven by modifiable metabolic factors. Increased visceral adipose tissue actively converts testosterone into oestrogen through the aromatase enzyme. This biochemical conversion creates a suppressive feedback loop that further reduces luteinising hormone (LH) output and subsequent testicular testosterone production. A waist circumference exceeding 102 cm (40 inches) serves as a concrete clinical metric for elevated metabolic and endocrine risk. [7,8]

Sleep Architecture

Disrupted sleep architecture is one of the most direct routes to secondary hypogonadism. Testosterone production is closely linked to sleep architecture, with levels rising from sleep onset and peaking during the first REM cycle in young men; slow-wave sleep also contributes to androgen secretion, and its suppression reduces morning testosterone levels. Both stages are implicated, and sleep fragmentation from any cause suppresses output substantially. Obstructive sleep apnoea in particular is a primary driver of hormonal suppression and should be screened for routinely in symptomatic patients. [9]

Medication-Induced Suppression

Clinicians must conduct a thorough pharmaceutical review during evaluation. Long-term opioid use, corticosteroids, and certain antidepressants exert a documented suppressive effect on the hypothalamic-pituitary-gonadal (HPG) axis, producing drug-induced secondary hypogonadism. Opioid use in particular warrants early screening given the prevalence of prescribed and non-prescribed use in the general population. [10]

Reference Ranges and Diagnostic Protocols

Reference intervals must be clearly delineated to support accurate clinical decision-making. Values below are drawn from established peer-reviewed sources and current guideline bodies. Assay method and laboratory-specific calibration should always be considered when interpreting individual results. [2,11]

Marker	Reference Range	Clinical Note
Total Testosterone	8.0 to 29.0 nmol/L	Population distribution range. The EAU 2024 treatment threshold for symptomatic patients is below 12 nmol/L. Diagnosis must not rely on a single value.
Free Testosterone (calculated, all adult men)	229 to 1072 pmol/L	Established via standardised equilibrium dialysis. Men aged 19 to 39 have a narrower reference of 415 to 1274 pmol/L. Assay method significantly affects reported values.
LH	1.7 to 8.6 IU/L	Required to distinguish primary from secondary hypogonadism. Elevated LH with low testosterone confirms primary testicular failure. Suppressed LH points to HPG axis dysfunction.
Oestradiol (E2)	40 to 161 pmol/L	Assess in the context of total testosterone ratio, particularly in patients with elevated BMI or visceral adiposity.

At WMG Health, our Testosterone Panel and the broader Hormone Specialist Panel both follow the standardised morning fasting sampling protocol described below, with results clinician-reviewed before release.

The Two-Sample Rule

In accordance with BSSM and EAU guidelines, a diagnosis of hypogonadism requires confirmation on two separate morning fasting samples, taken on different days within a 30-day window. This safeguard prevents initiation of long-term therapy based on transient hormonal suppression caused by acute illness, significant psychological stress, or disrupted sleep prior to a single draw. [3,12]

Clinical Note: LH Requirement

LH measurement is not optional. It distinguishes primary hypogonadism (testicular failure) from secondary hypogonadism (HPG axis dysfunction), which have distinct aetiologies and different management pathways. A diagnosis built solely on testosterone values without gonadotropin data is clinically incomplete. [6,12]

Safety, Governance, and Treatment Cautions

Lifestyle Intervention as First-Line

In alignment with conservative, evidence-based endocrinology, lifestyle modifications represent the non-negotiable first-line intervention. Weight reduction in obese patients, structured resistance training, and rigorous sleep hygiene must be prioritised and documented before pharmaceutical options are formally explored. In men with obesity-related functional hypogonadism, these measures alone can achieve clinically significant hormonal recovery. [7,13]

Testosterone Replacement Therapy: Side Effects and Monitoring

When intervention is clinically indicated, unmonitored therapy carries a significant risk. Management requires adherence to strict safety monitoring protocols across the following parameters:

• Polycythaemia. Testosterone therapy can cause increased red blood cell mass and elevated haematocrit. Elevated haematocrit thickens blood viscosity and elevates cardiovascular and thrombotic risk. Regular Full Blood Count monitoring is a non-negotiable safety requirement throughout the duration of treatment. [13]
• Fertility and structural changes. Exogenous testosterone suppresses endogenous LH and FSH, resulting in reduced spermatogenesis, testicular atrophy, and potentially irreversible infertility with prolonged use. Patients must receive pre-treatment counselling on this risk, with documented informed consent. [13]
• Prostate health. Prostate-Specific Antigen (PSA) tracking is mandatory throughout treatment. Testosterone therapy is an absolute contraindication in patients with untreated or active prostate or breast cancer. Severe lower urinary tract symptoms (LUTS, IPSS score above 19) represent a relative contraindication and require specialist review prior to initiation. [4]
• Prolactin. Hyperprolactinaemia is an organic, treatable cause of secondary hypogonadism and should be excluded during the diagnostic workup. Pituitary pathology, including prolactinoma, must be ruled out before TRT is considered, as testosterone supplementation will not correct the underlying hormonal suppression in such cases and may delay appropriate treatment. [4]

Clinical Governance and Service Pathway

To manage patient expectations and maintain transparent clinical boundaries, the operational structure of the medical pathway must be explicitly stated. The initial assessment service operates as a structured rapid diagnostic pathway: confirming or excluding biochemical hypogonadism, stratifying risk, and recommending lifestyle or referral pathways where appropriate.

Following stabilisation of diagnostic data and confirmation of pathology, onward referral pathways are established to transfer care to specialist endocrinologists within Westminster Medical Group for long-term management. Patients are informed of this tiered structure at the point of initial consultation, with written documentation of the transition criteria and expected timelines.

All documentation, CAPA reporting, and treatment monitoring adhere to the clinical governance standards of the Care Quality Commission and relevant BSSM and EAU guideline frameworks.

References

1. Goldman AL, Bhasin S, Wu FCW, Krishna M, Matsumoto AM, Jasuja R. A reappraisal of testosterone’s binding in circulation: physiological and clinical implications. Endocr Rev. 2017;38(4):302-324. doi:10.1210/er.2017-00025
2. Jasuja GK et al. Reference intervals for free testosterone in adult men measured using a standardised equilibrium dialysis procedure. Andrology. 2023;11(3):513-523. doi:10.1111/andr.13310
3. European Association of Urology. Guidelines on Sexual and Reproductive Health. EAU Guidelines Office, Arnhem, Netherlands. Updated April 2024. Available at: uroweb.org/guidelines/sexual-and-reproductive-health
4. Salonia A et al. EAU Guidelines on Male Hypogonadism. European Association of Urology, 2024. Full guideline PDF
5. Finkelstein JS et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369:1011-1022. doi:10.1056/NEJMoa1206168
6. Khera M, Torres LO, Grober ED, Morgentaler A, Miner M, Jones TH, Mills JN, Salonia A. Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sex Med Rev. 2025;13(4):548-573. doi:10.1093/sxmrev/qeaf036
7. Corona G et al. Obesity and late-onset hypogonadism. Mol Cell Endocrinol. 2015;418:120-133. doi:10.1016/j.mce.2015.06.031
8. Lunenfeld B et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Ageing Male. 2021;24(1):119-138. doi:10.1080/13685538.2021.1952853
9. Luboshitzky R et al. Disrupted testosterone secretion and sleep fragmentation in men with obstructive sleep apnoea. J Clin Endocrinol Metab. 2002;87(6):2541-2545. doi:10.1210/jcem.87.6.8627
10. Vold JH et al. Low testosterone among males in opioid agonist therapy and its association with fatigue and psychological distress. J Endocr Soc. 2025. Epub ahead of print. doi:10.1210/jendso/bvaf051
11. Bhasin S et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample: Framingham Heart Study. J Clin Endocrinol Metab. 2011;96(8):2430-2439. doi:10.1210/jc.2011-0440
12. Hackett G et al. The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice. J Sex Med. 2023;20(5):533-550. doi:10.5534/wjmh.221027
13. Bhasin S et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229

---

This article is for general clinical information and does not constitute personalised medical advice. If you have concerns about your symptoms, book an appointment or speak to your GP.